Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and... see more

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > crosstalk between senescent cells and CD8 T cell-dependent a
View:
Post by Noteable on Apr 06, 2023 10:35am

crosstalk between senescent cells and CD8 T cell-dependent a

The ability of ONCY's pelareorep to stimulate crosstalk in the TME has been attributed to pelareorep's further ability to stimulate the innate and adaptive immune system and prevent T cell loss/exhaustion that has been seen with long term PD-1 monoclonal antibody treatment.

April 04, 2023  - 
https://www.nature.com/articles/s41514-023-00105-5.pdf

In line with this finding, long-term administration of anti-PD-1 monoclonal antibodies enhances CD8 T cell-dependent clearance of p16+ senescent cells and alleviates the pathological sequelae linked to the overabundance of senescent cells in contexts of natural aging and steatohepatitis.
Comment by Noteable on Apr 06, 2023 11:04am
ONCY's pelareorep (reovirus) capabiltiy of remodeling an immunosuppressive / hypoxic tumor microenvironment (TME) results in the ability upregulating of turning "cold" tumors into "hot" tumors  through innate and adaptive immune responses to treat a variety of cancers, and overcoming the issue of T-Cell exhaustion through clonal proliferation of T-cell and the ...more  
Comment by Noteable on Apr 06, 2023 11:33am
Once again -- should read: "...results in the ability of turning "cold" tumors into "hot" tumors  .. through innate and adaptive immune responses to treat a variety of cancers, and overcoming the issue of T-Cell exhaustion ... "
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities